| Revenue growth | 43% YoY in Q1FY27; 32% YoY in FY26. |
|---|---|
| Margins | Q1FY27 EBITDA margin at 19% vs 15% YoY. |
| Demand visibility | Recurring demand for PTC; SDA demand driven by emission norms. |
Growth
Revenue up 43% YoY; EBITDA increased 86% YoY to ₹323 Mn; PAT surged 140% YoY to ₹160 Mn.
Outlook
Capex planned to boost capacities. Focused on niche specialty chemicals and expanding SDA/PASC segments.
Risks
High industry barriers with 1-6 year product approval cycles; potential geopolitical shifts impacting exports (75% of revenue).
Last quarter's promises, checked
Delivered
- Guided 25% revenue growth → delivered 43% YoY (= BEAT)
- Guided 20-22% EBITDA margin → delivered 19% (= PARTIAL)
- Guided SDA growth 20%+ → delivered SDA as primary driver (= BEAT)
Partly delivered
- Guided INR 100 Cr FY27 Capex → Ongoing capacity expansion (= PARTIAL)
Earnings Call filed with NSE, NSE: TATVA. Summary written with AI assistance from the document.
Tatva Chintan Pharma Chem Ltd: key numbers
- Share price
- ₹1,793.20
- Market cap
- ₹4,195 Cr
- Revenue (annual)
- ₹505.9 Cr
- Net profit (annual)
- ₹42.05 Cr
- P/E (TTM)
- 81.6×Sector 37.5×
- Promoter holding
- 72.02%+0.00% QoQ
- FII holding
- 3.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Tatva Chintan Pharma Chem Ltd
All →Tatva Chintan Pharma Chem Annual General Meeting
The company held its 30th Annual General Meeting on September 25, 2026. Shareholders considered and approved items including financial statements and director re-appointments.
Tatva Chintan Pharma Chem Credit Rating
CRISIL Ratings upgraded Tatva Chintan's long-term bank facilities to CRISIL A-/Stable and short-term facilities to CRISIL A2+. This upgrade reflects the company's improved credit profile.
Tatva Chintan Pharma Chem Investor Presentation: Key Takeaways
Tatva Chintan reported strong Q1 FY27 results with 43% YoY revenue growth. Strategy focuses on expanding SDA for Euro 7 standards and commercializing new pharma/semiconductor molecules.
- Call
- Guides 30% growth
Tatva Chintan Pharma Chem Earnings Call: Key Takeaways
Tatva Chintan reported Q4 FY26 revenue of ₹1,341 million (up 24% YoY) and EBITDA of ₹281 million (up 214% YoY), driven by improved product mix and operating leverage.
Tatva Chintan Pharma Chem Earnings Call: Key Takeaways
Tatva Chintan reported FY26 revenue of ₹5,059 Mn, up 32% YoY. Growth driven by SDA segment expansion and 'green' chemistry adoption.
Tatva Chintan Pharma Chem Earnings Call: Key Takeaways
Tatva Chintan reported a strong FY26 with revenue up 32% to ₹5,059 Mn and PAT surging 636% to ₹421 Mn. Growth driven by SDA and PASC segments.